Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth
Clicks: 323
ID: 118607
2004
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
81.2
/100
323 views
240 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #18 of 239 articles by views in Oncogene
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 239 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The transcriptional activity of the androgen receptor (AR) is regulated by interaction with various coregulators, one of which is β-catenin. Interest in the role of β-catenin in prostate cancer has been stimulated by reports showing that it is aberrantly expressed in the cytoplasm and/or nucleus in up to 38% of hormone-refractory tumours and that overexpression of β-catenin results in activation of AR transcriptional activity. We have examined the effect of depleting endogenous β-catenin on AR activity using Axin and RNA interference. Axin, which promotes β-catenin degradation, inhibited AR transcriptional activity. However, this did not require the β-catenin-binding domain of Axin. Depletion of β-catenin using RNA interference increased, rather than decreased, AR activity, suggesting that endogenous β-catenin is not a transcriptional coactivator for the AR. The glycogen synthase kinase-3 (GSK-3)-binding domain of Axin prevented formation of a GSK-3-AR complex and was both necessary and sufficient for inhibition of AR-dependent transcription. A second GSK-3-binding protein, FRAT, also inhibited AR transcriptional activity, as did the GSK-3 inhibitors SB216763 and SB415286. Finally, inhibition of GSK-3 reduced the growth of AR-expressing prostate cancer cell lines. Our observations suggest a potential new therapeutic application for GSK-3 inhibitors in prostate cancer.
| Reference Key |
mazor2004oncogeneinhibition
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Michal Mazor;Yoshiaki Kawano;Hanneng Zhu;Jonathan Waxman;Robert M Kypta;Michal Mazor;Yoshiaki Kawano;Hanneng Zhu;Jonathan Waxman;Robert M Kypta; |
| Journal | Oncogene |
| Year | 2004 |
| DOI |
doi:10.1038/sj.onc.1208068
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.